| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
MediPharm Labs Corp. (TSX:LABS) (OTCQB:MEDIF) (FSE: MLZ) reported its financial results for the three months ended September 30, 2023, with a revenue of C$8.5 million. This reflects a decrease of around C$1 million sequentially but an increase of C$1.3 million over the year.
CEO David Pidduck emphasized the company's focus on margins, cost reductions and profitability, noting the strong balance sheet and improved profitability for strategic investments in revenue growth.
Additionally, the company settled a 'long-lasting' commercial agreement dispute receiving a total of C$9M. This includes net cash of C$7.3M collected in October, C$1M in Tilray Brands, Inc. (NASDAQ:TLRY) cannabis products, and a four-year agreement where Tilray will purchase C$0.5M of MediPharm products.
Greg Hunter, CFO of MediPharm, highlighted continued progress in Q3, emphasizing improvements in gross margins, expense reduction, and reduced cash burn toward profitability.
MEDIF's shares were trading 2.23% down at $0.0503 per share on Tuesday afternoon.
Related News: